DUNEDIN, New Zealand – Pacific Edge (NZX, ASX: PEB) today reports successful execution of strategic initiatives to focus the company on the development of its advanced cancer diagnostic tests for inclusion in clinical guidelines
Pacific Edge Limited reported earnings results for the full year ended March 31, 2024. For the full year, the company reported sales was NZD 23.91 million compared to NZD 19.62 million a year ago..